Sugi Predict

Sugi Predict / Compounds / SCHEMBL376730

SCHEMBL376730

SCHEMBL376730

OC[C@H](NO)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.47
▸ ROCK2 O75116 2/20 0.46
▸ ROCK1 Q13464 2/20 0.46
▸ MAPK13 O15264 1/20 0.46
▸ RPS6KA5 O75582 1/20 0.46
▸ MAP4K4 O95819 1/20 0.46
▸ PAK4 O96013 1/20 0.46
▸ PRKCG P05129 1/20 0.46
▸ CDK1 P06493 1/20 0.46
▸ PRKACA P17612 1/20 0.46
▸ RPS6KB1 P23443 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ AKT1 P31749 1/20 0.46
▸ AKT2 P31751 1/20 0.46
▸ CLK2 P49760 1/20 0.46
▸ GSK3A P49840 1/20 0.46
▸ GSK3B P49841 1/20 0.46
▸ IRAK1 P51617 1/20 0.46
▸ RPS6KA3 P51812 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2079846 1.00 RIPK1 (0.47) RIPK1ROCK2ROCK1MAPK13RPS6KA5
SCHEMBL2079847 1.00 RIPK1 (0.47) RIPK1ROCK2ROCK1MAPK13RPS6KA5
SCHEMBL10526965 0.83 RIPK1 (0.49) RIPK1ROCK2ROCK1MAPK13RPS6KA5
SCHEMBL17864360 0.82 PRKACA (0.49) RIPK1ROCK2ROCK1MAPK13RPS6KA5
SCHEMBL10211441 0.81 RIPK1 (0.47) RIPK1ROCK2ROCK1MAPK13RPS6KA5
SCHEMBL10211434 0.81 RIPK1 (0.47) RIPK1ROCK2ROCK1MAPK13RPS6KA5
SCHEMBL11744344 0.79 SLC6A2 (0.50) TRPA1KDM4EL3MBTL1CYP2D6SLC6A2
SCHEMBL1520851 0.79 LMNA (0.52) RIPK1EPHX2KDM4E
SCHEMBL18539292 0.79 AOC3 (0.52) RIPK1ROCK2ROCK1MAPK13RPS6KA5
SCHEMBL16323165 0.79 LMNA (0.52) RIPK1EPHX2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12465590-B2 Oxalamido-substituted tricyclic inhibitors of hepatitis b virus OSPEDALE SAN RAFFAELE S.R.L. (IT) 2025-11-11 — — US disclosed
CN-119409710-A Oxamide substituted hepatitis b virus tricyclic inhibitors 圣拉斐尔医院有限公司 2025-02-11 — — CN disclosed
CN-114555608-B Oxamide substituted hepatitis b virus tricyclic inhibitors 圣拉斐尔医院有限公司 2024-11-01 — — CN disclosed
EP-3833672-B1 TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE SRL (IT) 2024-09-18 — — EP disclosed
CN-113272309-B Tricyclic inhibitors of hepatitis b virus 圣拉斐尔医院有限公司 2024-02-23 — — CN disclosed
US-20230076319-A1 INHIBITORS OF HEPATITIS B VIRUS ANTIOS THERAPEUTICS INC (US) 2023-03-09 — — US disclosed
US-11504382-B2 Tricyclic inhibitors of Hepatitis B virus Antios Therapeutics, Inc. (US) 2022-11-22 — — US disclosed
US-20220241241-A1 OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM (IT) 2022-08-04 — — US disclosed
CN-114555608-A Oxamide substituted tricyclic inhibitors of hepatitis b virus 分子遗传国家研究所(INGM) 2022-05-27 — — CN disclosed
US-20220110943-A1 TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE S.R.L. (IT) 2022-04-14 — — US disclosed
EP-3741762-A1 OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS IRBM S.P.A. (IT) 2020-11-25 — — EP disclosed
CN-107445852-A Preparation method of D-indanyl glycine 浙江工业大学 2017-12-08 — — CN disclosed
US-8518952-B2 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors PFIZER INC. (US) 2013-08-27 — — US disclosed
EP-2328890-B1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER (US) 2012-01-25 — — EP disclosed
EP-2328890-B1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER (US) 2012-01-25 — — EP disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 — — US disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 — — US disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 — — US disclosed
EP-2328890-A1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS Pfizer Inc. (US) 2011-06-08 — — EP disclosed
WO-2010016005-A1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC. (US) 2010-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12465590-B2 Oxalamido-substituted tricyclic inhibitors of hepatitis b virus OAT, SLC10A1, OTC RIPK1 1435/4885ROCK2 4084/4885ROCK1 3675/4885
US-11504382-B2 Tricyclic inhibitors of Hepatitis B virus HAVCR2, NR1H4, HCCS RIPK1 1646/4885ROCK2 2359/4885ROCK1 2308/4885
US-20220110943-A1 TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS HAVCR2, NR1H4, HCCS RIPK1 1646/4885ROCK2 2359/4885ROCK1 2308/4885
US-20230076319-A1 INHIBITORS OF HEPATITIS B VIRUS HAVCR2, HDGF, SLC10A1 RIPK1 1672/4885ROCK2 1347/4885ROCK1 1248/4885
US-20220241241-A1 OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS OAT, OTC, SLC10A1 RIPK1 947/4885ROCK2 3825/4885ROCK1 3820/4885
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS CHKA, CSNK1A1, CHKB RIPK1 517/4885ROCK2 953/4885ROCK1 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.